Log in

Opiant Pharmaceuticals Stock Forecast, Price & News

-0.11 (-1.23 %)
(As of 09/18/2020 09:34 PM ET)
Today's Range
Now: $8.82
50-Day Range
MA: $8.84
52-Week Range
Now: $8.82
Volume15,700 shs
Average Volume39,182 shs
Market Capitalization$37.56 million
P/E Ratio5.13
Dividend YieldN/A
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.
Read More
Opiant Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.03 out of 5 stars

Industry, Sector and Symbol

Industry Metal mining
Current SymbolNASDAQ:OPNT



Sales & Book Value

Annual Sales$40.52 million
Cash Flow$0.29 per share
Book Value$8.41 per share


Net Income$11.59 million


Market Cap$37.56 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
-0.11 (-1.23 %)
(As of 09/18/2020 09:34 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OPNT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions

How has Opiant Pharmaceuticals' stock price been impacted by COVID-19?

Opiant Pharmaceuticals' stock was trading at $10.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OPNT stock has decreased by 18.7% and is now trading at $8.82.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Opiant Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Opiant Pharmaceuticals

When is Opiant Pharmaceuticals' next earnings date?

Opiant Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Opiant Pharmaceuticals

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) issued its quarterly earnings results on Thursday, August, 6th. The technology company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.26. The technology company earned $6.31 million during the quarter, compared to the consensus estimate of $6.47 million. Opiant Pharmaceuticals had a negative return on equity of 2.43% and a net margin of 25.32%.
View Opiant Pharmaceuticals' earnings history

What price target have analysts set for OPNT?

1 analysts have issued 12-month price targets for Opiant Pharmaceuticals' stock. Their forecasts range from $42.00 to $42.00. On average, they expect Opiant Pharmaceuticals' share price to reach $42.00 in the next twelve months. This suggests a possible upside of 376.2% from the stock's current price.
View analysts' price targets for Opiant Pharmaceuticals

Are investors shorting Opiant Pharmaceuticals?

Opiant Pharmaceuticals saw a decline in short interest in August. As of August 31st, there was short interest totaling 10,500 shares, a decline of 29.5% from the August 15th total of 14,900 shares. Based on an average daily volume of 45,800 shares, the short-interest ratio is presently 0.2 days. Approximately 0.3% of the shares of the company are sold short.
View Opiant Pharmaceuticals' Short Interest

Who are some of Opiant Pharmaceuticals' key competitors?

What other stocks do shareholders of Opiant Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include AcelRx Pharmaceuticals (ACRX), Cara Therapeutics (CARA), Synchrony Financial (SYF), Vodafone Group (VOD), Corbus Pharmaceuticals (CRBP), Cyberark Software (CYBR), AT&T (T), Agenus (AGEN), Aurinia Pharmaceuticals (AUPH) and Cronos Group (CRON).

Who are Opiant Pharmaceuticals' key executives?

Opiant Pharmaceuticals' management team includes the following people:
  • Dr. Roger Crystal, CEO & Director (Age 43)
  • Mr. David D. O'Toole, Chief Financial Officer (Age 60)
  • Dr. Phil Skolnick, Chief Scientific Officer (Age 72)
  • Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 49)
  • Mr. Quan Vu, VP of Corp. Devel.

What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

Who are Opiant Pharmaceuticals' major shareholders?

Opiant Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Perritt Capital Management Inc. (0.69%) and Advisor Group Holdings Inc. (0.08%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, David D O'toole, Gabrielle Alison Silver, Michael Sinclair, Phil Skolnick, Roger Crystal and Thomas T Thomas.
View institutional ownership trends for Opiant Pharmaceuticals

Which major investors are selling Opiant Pharmaceuticals stock?

OPNT stock was sold by a variety of institutional investors in the last quarter, including Perritt Capital Management Inc., and Advisor Group Holdings Inc..
View insider buying and selling activity for Opiant Pharmaceuticals

How do I buy shares of Opiant Pharmaceuticals?

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Opiant Pharmaceuticals' stock price today?

One share of OPNT stock can currently be purchased for approximately $8.82.

How big of a company is Opiant Pharmaceuticals?

Opiant Pharmaceuticals has a market capitalization of $37.56 million and generates $40.52 million in revenue each year. The technology company earns $11.59 million in net income (profit) each year or $0.20 on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe.

What is Opiant Pharmaceuticals' official website?

The official website for Opiant Pharmaceuticals is www.opiant.com.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.